| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-24588SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56698SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-654SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-25274 | |||
| BSA Free | NBP2-27332SS | |||
| Azide and BSA Free | NBP2-25274SS | |||
| Azide and BSA Free | NBP2-80982 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56571SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-27416 | |||
| BSA Free | NB100-56712SS | |||
| Azide and BSA Free | NBP2-27416SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56536SS | |||
| Azide and BSA Free | NBP2-37704 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB300-504-0.025mg | |||
![Immunohistochemistry-Paraffin: RIPK3/RIP3 Antibody [NBP2-24588] - Analysis of RIP3 using polyclonal RIPK3/RIP3 Antibody [NBP2-24588]. Human pancreas probed with RIPK3/RIP3 antibody at 10 ug/ml.](http://images.novusbio.com/fullsize/RIPK3-RIP3-Antibody-Immunohistochemistry-Paraffin-NBP2-24588-img0004.jpg "Immunohistochemistry-Paraffin: RIPK3/RIP3 Antibody [NBP2-24588] - Analysis of RIP3 using polyclonal RIPK3/RIP3 Antibody [NBP2-24588]. Human pancreas probed with RIPK3/RIP3 antibody at 10 ug/ml.")
![<b>Biological Strategies Validation. </b>Western Blot: RIPK3/RIP3 Antibody [NBP2-24588] - Representative western blot analysis of RIP1, RIPK3/RIP3, and beta-actin in WI-38 NCs and IR-SCs 24 h after incubation with Veh or 10 uM PL. A cell lysate of etoposide-treated Jurkat cells was used as a positive control. Image collected and cropped by CiteAb from the following publication (//www.aging-us.com/article/101100/text) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/RIPK3-RIP3-Antibody-Western-Blot-NBP2-24588-img0006.jpg)
![Immunocytochemistry/Immunofluorescence: RIPK3/RIP3 Antibody [NBP2-24588] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with RIPK3/RIP3 Antibody [NBP2-24588] at a 1:200 dilution overnight at 4C and detected with DyLight 488 (Green) at a 1:500 dilution. Alpha tubulin was used at a 1:1000 dilution as a co-stain and detected with DyLight 550 (Red) at a 1:500 dilution. Nuclei were detected with DAPI (Blue) at 2.0ug/ml in 1X PBS. Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/RIPK3-RIP3-Antibody-Immunocytochemistry-Immunofluorescence-NBP2-24588-img0003.jpg)
![Western Blot: RIPK3/RIP3 Antibody [NBP2-24588] - Analysis of RIP3 using polyclonal RIPK3/RIP3 antibody [NBP2-24588]. Human tissue blot probed with 5 ug/ml of RIP3 antibody: 1) brain, 2) heart, 3) small intestine, 4) kidney, 5) liver, 6) lung, 7) skeletal muscle, 8) stomach, 9) spleen, 10) ovary, 11) testis, 12) placenta probed at 5 ug/ml, 13) Ramos cell lysate probed at 7 ug/ml. Theoretical molecular weight 56.7 kDa.](http://images.novusbio.com/fullsize/RIPK3-RIP3-Antibody-Western-Blot-NBP2-24588-img0005.jpg)
![Western Blot: RIPK3/RIP3 Antibody - BSA Free [NBP2-24588] - HOIP limits the activity of TRAIL‐induced apoptosis‐ & necroptosis‐mediating signalling complexesControl & HOIP KO HeLa cells were treated with FLAG‐lz‐TRAIL (500 ng/ml) for the indicated times. The TRAIL complex I was immunoprecipitated via anti‐FLAG beads. Complex II was isolated by immunoprecipitating caspase‐8 from complex I‐depleted lysates. Western blot was performed using the indicated antibodies. * indicates unspecific bands.WT & HOIP‐deficient TNF KO MEFs, pre‐treated for 1 h with zVAD, were stimulated with iz‐TRAIL (1 μg/ml) for the indicated times. FADD‐containing complexes were immunoprecipitated & analysed by Western blot.Data information: See also Fig EV2. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28258062), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-24588_rabbit-polyclonal-ripk3-rip3-antibody-31020241534394.jpg)
![Western Blot: RIPK3/RIP3 Antibody - BSA Free [NBP2-24588] - The catalytic activity of HOIP contributes to preventing TRAIL‐induced apoptosis but is dispensable for preventing necroptosisLysates from control or HOIP KO K562 cells reconstituted w/ empty vector, HOIP WT or HOIP C885S analysed by WB.HOIP KO K562 cells reconstituted w/ empty vector, HOIP WT or HOIP C885S, pre‐treated w/ zVAD and/or Nec‐1s for 1 h as indicated, treated w/ iz‐TRAIL (1 μg/ml) for 24 h. Percentage of cell death determined by flow cytometry after PI labelling (n = 5; mean ± SEM). *P < 0.05, **P < 0.01; statistics performed using ANOVA.Control & HOIP KO K562 cells reconstituted w/ empty vector, HOIP WT or HOIP C885S treated w/ iz‐TRAIL (100 ng/ml) for the indicated times. Lysates analysed w/ the indicated antibodies.Lysates from TNF KO HOIP KO MEFs reconstituted w/ empty vector, HOIP WT or HOIP C885S analysed by WB.TNF KO HOIP KO MEFs reconstituted w/ empty vector, HOIP WT or HOIP C885S, pre‐treated w/ zVAD & Nec‐1s for 1 h as indicated, treated w/ iz‐TRAIL (1 μg/ml) for 24 h. Percentage of cell death determined by flow cytometry after PI labelling (n = 4; mean ± SEM). *P < 0.05, ***P < 0.001; statistics performed using ANOVA.TNF KO HOIP KO MEFs reconstituted w/ empty vector, pre‐treated w/ zVAD and/or the RIPK3 inhibitor GSK'872 for 1 h as indicated, treated w/ iz‐TRAIL (1 μg/ml) for 24 h. Percentage of cell death determined by flow cytometry after PI labelling (n = 3; mean ± SEM). *P < 0.05; statistics performed using t‐test.TNF KO HOIP KO MEFs reconstituted w/ empty vector, HOIP WT or HOIP C885S, pre‐treated w/ zVAD for 1 h, treated w/ iz‐TRAIL (1 μg/ml) for the indicated times. FADD‐containing complexes immunoprecipitated & analysed by WB. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28258062), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-24588_rabbit-polyclonal-ripk3-rip3-antibody-310202416114733.jpg)
![Western Blot: MyD88 Antibody [NB100-56698] - The ability of PTX to induce the IL-1 Beta IL-6 cascade depends on the integrity of its multimeric structure and enzymatic activity.Western blots revealing the presence of mature IL-1 Beta, cleaved Casp1, TLR4 and Myd88 in peritoneal fluid or peritoneal cell lysates from mice killed 6 h after injection of PBS, wild-type PTX or PTXmut. Arrowheads indicate the cleaved forms. Beta-actin was used as loading control. Sample size: 8 per group. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.ppat.1004150) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/MyD88-Antibody-Western-Blot-NB100-56698-img0007.jpg "<b>Biological Strategies Validation. </b>Western Blot: MyD88 Antibody [NB100-56698] - The ability of PTX to induce the IL-1 Beta IL-6 cascade depends on the integrity of its multimeric structure and enzymatic activity.Western blots revealing the presence of mature IL-1 Beta, cleaved Casp1, TLR4 and Myd88 in peritoneal fluid or peritoneal cell lysates from mice killed 6 h after injection of PBS, wild-type PTX or PTXmut. Arrowheads indicate the cleaved forms. Beta-actin was used as loading control. Sample size: 8 per group. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.ppat.1004150) licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: MyD88 Antibody [NB100-56698] - Raw264.7 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.5% Triton-X100. The cells were incubated with anti-MyD88 at 2 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Alpha tubulin (DM1A) NB100-690 was used as a co-stain at a 1:1000 dilution and detected with an anti-mouse Dylight 550 (Red) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/MyD88-Antibody-Immunocytochemistry-Immunofluorescence-NB100-56698-img0008.jpg)
![Immunohistochemistry-Paraffin: MyD88 Antibody [NB100-56698] - Tissue section of human liver using at 1:100 dilution. This antibody generated a very specific cytoplasmic staining in the hepatocytes as well as the Kupffer cells (hepatic macrophages), and the latter showed the most intense staining among all other cell types in the section.](http://images.novusbio.com/fullsize/MyD88-Antibody-Immunohistochemistry-Paraffin-NB100-56698-img0005.jpg)
![Western Blot: MyD88 Antibody [NB100-56698] - Analysis of MyD88 in human spleen cell lysate using 0.5 ug/ml of NB100-56698.](http://images.novusbio.com/fullsize/MyD88-Antibody-Western-Blot-NB100-56698-img0003.jpg)
![Immunohistochemistry-Paraffin: MyD88 Antibody [NB100-56698] - Tissue section of human liver using at 1:100 dilution. This antibody generated a very specific cytoplasmic staining in the hepatocytes as well as the Kupffer cells (hepatic macrophages), and the latter showed the most intense staining among all other cell types in the section.](http://images.novusbio.com/fullsize/MyD88-Antibody-Immunohistochemistry-Paraffin-NB100-56698-img0004.jpg)
![Western Blot: MyD88 Antibody - BSA Free [NB100-56698] - TLR & other LPS-response elements in LPS-stimulated HSCs.(A) Microarray data show time-dependent changes in the indicated transcripts. For clarity control gene expression at 1 & 24h is offset to 0.5h & 24.5h respectively. (B) A representative Western blot (left pane) & densitometric analysis (right panel) of the indicated molecules at 24h following stimulation with 10 ng/ml LPS. (C) qPCR analysis of the indicated molecules with p values showing statistical differences. The values (B,C) shown are form 3 separate determinations from different batches of HSCs. Statistical significance was derived from student’s t-test using Microsoft-excel program. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0082159), licensed under a CC0-1.0 license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56698_rabbit-polyclonal-myd88-antibody-310202415371913.jpg)
![Western Blot: HIF-1 alpha Antibody [NB100-654] - Effects of in vitro hypoxia on the expression of mouse HIF-1 alpha in HIF-1 alpha+/- and HIF-1 alpha+/+ astrocytes. Confluent astrocyte monolayers of both cell types were exposed to a 6 h in vitro hypoxia. HIF-1 alpha mRNA expression was determined by RT-PCR as described in Materials and Methods. Each bar represents the mean +/- SD of relative density/volumes of the bands on film negatives from at least three experiments. Asterisks and number sign indicate significant difference (p < 0.01; one-way ANOVA, followed by multiple comparisons among means). Image collected and cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-4-12), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Western-Blot-NB100-654-img0009.jpg "<b>Biological Strategies Validation, Genetic Strategies Validation and Orthogonal Strategies Validation.</b>Western Blot: HIF-1 alpha Antibody [NB100-654] - Effects of in vitro hypoxia on the expression of mouse HIF-1 alpha in HIF-1 alpha+/- and HIF-1 alpha+/+ astrocytes. Confluent astrocyte monolayers of both cell types were exposed to a 6 h in vitro hypoxia. HIF-1 alpha mRNA expression was determined by RT-PCR as described in Materials and Methods. Each bar represents the mean +/- SD of relative density/volumes of the bands on film negatives from at least three experiments. Asterisks and number sign indicate significant difference (p < 0.01; one-way ANOVA, followed by multiple comparisons among means). Image collected and cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-4-12), licensed under a CC-BY license.")
![<b>Biological Strategies Validation, Genetic Strategies Validation and Orthogonal Strategies Validation.</b>Western Blot: HIF-1 alpha Antibody [NB100-654] - Effects of CoCl2 treatment on HIF-1 alpha expression in mouse astrocytes. Western blots using nuclear proteins show that both hypoxia (H) and CoCl2 (Co) up-regulated HIF-1 alpha protein in HIF-1 alpha+/+ and HIF-1 alpha+/- cells. There was no HIF-1 alpha protein detected in control cells. Image collected and cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-4-12), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Western-Blot-NB100-654-img0008.jpg)
![Immunohistochemistry-Paraffin: HIF-1 alpha Antibody [NB100-654] - IHC analysis of a formalin-fixed paraffin-embedded tissue section of human endometrium carcinoma AN3CA cell line based xenograft using rabbit polyclonal HIF-1 alpha antibody NB100-654 at 1:300 dilution. The signal was developed using HRP-labelled secondary antibody and DAB reagent, and the section was further counterstained using hematoxylin. The tested section depicted mainly a diffused cytoplasmic staining but there were some cells which showed nuclear signal also (representing hypoxic cells).](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Immunohistochemistry-Paraffin-NB100-654-img0006.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: HIF-1 alpha Antibody [NB100-654] - HIF1-alpha analysis using NB100-654. Image submitted from verified customer review.](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Western-Blot-NB100-654-img0007.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: HIF-1 alpha Antibody [NB100-654] - Detection of HIF-1 alpha in cobalt chloride treated/untreated COS-7 nuclear extracts using NB100-654.](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Western-Blot-NB100-654-img0003.jpg)
![Simple Western: HIF-1 alpha Antibody [NB100-654] - Simple Western lane view shows a specific band for HIF-1 alpha in 0.5 mg/ml of Hypoxic HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Simple-Western-NB100-654-img0005.jpg)
![Gel Super Shift Assays: HIF-1 alpha Antibody [NB100-654] - Mouse HIF-1 alpha+/+ and HIF-1 alpha+/- cells were exposed to hypoxia or 125 uM CoCl2 for 6 h, nuclear extracts were then prepared and EMSA carried out. HIF-1 isolated from hypoxia or CoCl2-treated cells bound to the wild-type probe (lanes #1-6) but not to the mutant probe (lanes #7-12). HIF-1/DNA complex was detected in hypoxia (H)-or CoCl2 (Co)-treated cells (lanes #2, 3, 5, 6) but not in control (C) cells (lanes #1, 4). More complex (darker band) was seen in hypoxia-or CoCl2-treated HIF-1 alpha+/+ cells (lanes #2, 3) than that in hypoxia-or CoCl2-treated HIF-1 alpha+/- cells (lanes #5, 6). Supershift assay showed that the HIF-1/DNA complex was shifted up in the presence of wild-type (wt) oligo probe and 4 ug HIF-1 alpha antiboby (lanes #13 & 14). Image collected and cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-4-12), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Gel-Super-Shift-Assays-NB100-654-img0011.jpg)
![Western Blot: HIF-1 alpha Antibody - BSA Free [NB100-654] - Effects of CoCl2 treatment on HIF-1 alpha expression in mouse astrocytes. (A) The cells were incubated in the presence or absence of 125 μM CoCl2 for 6 hr. HIF-1 alpha mRNA expression was determined by RT-PCR. Each bar represents the mean ± SD of relative density/volumes of the bands on film negatives from at least three experiments. Asterisk & number sign indicate significant difference compared to relevant controls (p < 0.01; one-way ANOVA, followed by multiple comparisons among means). (B) Western blots using nuclear proteins show that both hypoxia (H) & CoCl2 (Co) up-regulated HIF-1 alpha protein in HIF-1 alpha +/+ & HIF-1 alpha +/- cells. There was no HIF-1 alpha protein detected in control cells (C). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/17474992), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-654_rabbit-polyclonal-hif-1-alpha-antibody-31020241529191.jpg)
![Western Blot: HIF-1 alpha Antibody - BSA Free [NB100-654] - Aberrant HIF1 alpha expression in PDAC cancer associated fibroblastsA. The level of MCT4 was determined in the indicated established pancreatic cancer cell lines & CAF cultures by immunoblotting. B. The level of MCT1 was determined in the indicated established pancreatic cancer cell lines & CAF cultures by immunoblotting. C. HIF alpha & MCT4 levels were determined by immunoblotting following the knockdown of HIF1 alpha with RNAi or the induction of hypoxia through the use of CoCl2. D. The stability of HIF1 alpha was evaluated in CAFs following treatment with cycloheximide. E. HIF1 alpha was detected by immunoblotting in the presence of cycloheximide in the absence or presence of the proteasome inhibitor MG132. F. HIF1 alpha protein levels were determined in the absence & presence of DMOG. G. RNA levels of the indicated genes as determined by microarray analyses (**p < 0.01 for tumor cell line vs. CAF). H. MG132 was used to interrogate the synthetic rate of HIF1 alpha protein in the indicated cell lines. I. The expression of HIF1 alpha target genes was evaluated in the indicated cell lines by microarray analysis (**p < 0.01 for tumor cell vs. CAF). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27623078), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-654_rabbit-polyclonal-hif-1-alpha-antibody-31020241553714.jpg)
![Western Blot: HIF-1 alpha Antibody - BSA Free [NB100-654] - Aberrant HIF1 alpha expression in PDAC cancer associated fibroblastsA. The level of MCT4 was determined in the indicated established pancreatic cancer cell lines & CAF cultures by immunoblotting. B. The level of MCT1 was determined in the indicated established pancreatic cancer cell lines & CAF cultures by immunoblotting. C. HIF alpha & MCT4 levels were determined by immunoblotting following the knockdown of HIF1 alpha with RNAi or the induction of hypoxia through the use of CoCl2. D. The stability of HIF1 alpha was evaluated in CAFs following treatment with cycloheximide. E. HIF1 alpha was detected by immunoblotting in the presence of cycloheximide in the absence or presence of the proteasome inhibitor MG132. F. HIF1 alpha protein levels were determined in the absence & presence of DMOG. G. RNA levels of the indicated genes as determined by microarray analyses (**p < 0.01 for tumor cell line vs. CAF). H. MG132 was used to interrogate the synthetic rate of HIF1 alpha protein in the indicated cell lines. I. The expression of HIF1 alpha target genes was evaluated in the indicated cell lines by microarray analysis (**p < 0.01 for tumor cell vs. CAF). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27623078), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-654_rabbit-polyclonal-hif-1-alpha-antibody-31020241682154.jpg)
![Western Blot: HIF-1 alpha Antibody - BSA Free [NB100-654] - Aberrant HIF1 alpha expression in PDAC cancer associated fibroblastsA. The level of MCT4 was determined in the indicated established pancreatic cancer cell lines & CAF cultures by immunoblotting. B. The level of MCT1 was determined in the indicated established pancreatic cancer cell lines & CAF cultures by immunoblotting. C. HIF alpha & MCT4 levels were determined by immunoblotting following the knockdown of HIF1 alpha with RNAi or the induction of hypoxia through the use of CoCl2. D. The stability of HIF1 alpha was evaluated in CAFs following treatment with cycloheximide. E. HIF1 alpha was detected by immunoblotting in the presence of cycloheximide in the absence or presence of the proteasome inhibitor MG132. F. HIF1 alpha protein levels were determined in the absence & presence of DMOG. G. RNA levels of the indicated genes as determined by microarray analyses (**p < 0.01 for tumor cell line vs. CAF). H. MG132 was used to interrogate the synthetic rate of HIF1 alpha protein in the indicated cell lines. I. The expression of HIF1 alpha target genes was evaluated in the indicated cell lines by microarray analysis (**p < 0.01 for tumor cell vs. CAF). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27623078), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-654_rabbit-polyclonal-hif-1-alpha-antibody-310202415523946.jpg)
![Western Blot: HIF-1 alpha Antibody - BSA Free [NB100-654] - Aberrant HIF1 alpha expression in PDAC cancer associated fibroblastsA. The level of MCT4 was determined in the indicated established pancreatic cancer cell lines & CAF cultures by immunoblotting. B. The level of MCT1 was determined in the indicated established pancreatic cancer cell lines & CAF cultures by immunoblotting. C. HIF alpha & MCT4 levels were determined by immunoblotting following the knockdown of HIF1 alpha with RNAi or the induction of hypoxia through the use of CoCl2. D. The stability of HIF1 alpha was evaluated in CAFs following treatment with cycloheximide. E. HIF1 alpha was detected by immunoblotting in the presence of cycloheximide in the absence or presence of the proteasome inhibitor MG132. F. HIF1 alpha protein levels were determined in the absence & presence of DMOG. G. RNA levels of the indicated genes as determined by microarray analyses (**p < 0.01 for tumor cell line vs. CAF). H. MG132 was used to interrogate the synthetic rate of HIF1 alpha protein in the indicated cell lines. I. The expression of HIF1 alpha target genes was evaluated in the indicated cell lines by microarray analysis (**p < 0.01 for tumor cell vs. CAF). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27623078), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-654_rabbit-polyclonal-hif-1-alpha-antibody-31020241553515.jpg)
![Flow Cytometry: TLR7 Antibody (4G6) [NBP2-27332] - THP-1 cells were stained with TLR7 (4G) NBP2-27332 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature, followed by Dylight488-conjugated anti-mouse secondary antibody.](http://images.novusbio.com/fullsize/TLR7-Antibody-4G6-Flow-Cytometry-NBP2-27332-img0008.jpg "Flow Cytometry: TLR7 Antibody (4G6) [NBP2-27332] - THP-1 cells were stained with TLR7 (4G) NBP2-27332 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature, followed by Dylight488-conjugated anti-mouse secondary antibody.")
![Flow (Intracellular): TLR7 Antibody (4G6) [NBP2-27332] - Analysis using the PE conjugate of NBP2-27332. Staining of TLR7 in 10^6 human BDCM cells (red) and 0.5 ug of mouse IgG1 isotype control (green). this antibody was used for this test.](http://images.novusbio.com/fullsize/TLR7-Antibody-4G6-Flow-Intracellular-NBP2-27332-img0009.jpg)
![Flow Cytometry: TLR7 Antibody (4G6) [NBP2-27332] - Analysis using Azide Free version of NBP2-27332. THP-1 cells were stained with TLR7 (4G) NBP2-25274 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin.](http://images.novusbio.com/fullsize/TLR7-Antibody-4G6-Flow-Cytometry-NBP2-27332-img0012.jpg)
![Western Blot: TLR7 Antibody (4G6) - BSA Free [NBP2-27332] - The protein of TLR7 were pull down by miR-138-biotin / miR-mut-138-biotin with Streptavidin agarose beads in BV2 cells. Image collected and cropped by CiteAb from the following publication (//www.ncbi.nlm.nih.gov/pmc/articles/PMC7710131/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR7-Antibody-4G6-BSA-Free-Western-Blot-NBP2-27332-img0017.jpg)
![Immunohistochemistry: TLR7 Antibody (4G6) [NBP2-27332] - Analysis of a FFPE tissue section of human brain using 1:200 dilution of TLR7 [4G6] antibody. The staining was developed using HRP labeled anti-rabbit secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin.](http://images.novusbio.com/fullsize/TLR7-Antibody-4G6-Immunohistochemistry-NBP2-27332-img0016.jpg)
![Flow Cytometry: TLR7 Antibody (4G6) [NBP2-27332] - An intracellular stain was performed on Ramos cells with TLR7 Antibody (4G6) NBP2-27332 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).](http://images.novusbio.com/fullsize/TLR7-Antibody-4G6-Flow-Cytometry-NBP2-27332-img0015.jpg)
![Western Blot: TLR7 Antibody (4G6) [NBP2-27332] - TLR7 antibodies tested at 2 ug/ml on recombinant partial hTLR7 protein (amino acids 562-839). NB100-56682 and NBP2-24767 immunogen sequences are not present in recombinant protein; *NB100-56588 is not recommended for use in western blot.](http://images.novusbio.com/fullsize/TLR7-Antibody-4G6-Western-Blot-NBP2-27332-img0005.jpg)
![Western Blot: TLR7 Antibody (4G6) [NBP2-27332] - Analysis using Azide Free version of NBP2-27332. Human TLR7 antibody in Ramos and transfected 293T lysate using TLR7 monoclonal antibody at 10 ug/ml.](http://images.novusbio.com/fullsize/TLR7-Antibody-4G6-Western-Blot-NBP2-27332-img0011.jpg)
![Flow Cytometry: TLR7 Antibody (4G6) [NBP2-27332] - Analysis of TLR7 in human monocytes using 2 ug of TLR7 monoclonal antibody (red) and 2 ug of mouse IgG1 isotype control antibody (green). TLR intracellular flow kit was used for this test, and an anti-mouse IgG PE conjugated secondary antibody .](http://images.novusbio.com/fullsize/TLR7-Antibody-4G6-Flow-Cytometry-NBP2-27332-img0002.jpg)
![Flow Cytometry: TLR7 Antibody (4G6) [NBP2-27332] - An intracellular stain was performed on Daudi cells with TLR7 Antibody (4G6) NBP2-27332 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).](http://images.novusbio.com/fullsize/TLR7-Antibody-4G6-Flow-Cytometry-NBP2-27332-img0013.jpg)
![Flow Cytometry: TLR7 Antibody (4G6) [NBP2-27332] - An intracellular stain was performed on Raji cells with TLR7 Antibody (4G6) NBP2-27332 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).](http://images.novusbio.com/fullsize/TLR7-Antibody-4G6-Flow-Cytometry-NBP2-27332-img0014.jpg)
![Western Blot: TLR7 Antibody (4G6) - BSA Free [NBP2-27332] - ADEV miR‐138 interacts with murine TLR7 in the endosomes. (A) Representative fluorescence images of mouse primary microglial cells incubated with Exo‐Fect+ADEVs+Cy5‐miR138 or Exo‐Fect+Cy5‐miR138 (without ADEVs) or Exo‐Fect+ADEVs+miR138 (unstained) for 30 min followed by immunostaining of (A) an early endosome marker (EEA1, Green) & (B) TLR7 (Green). Exo‐fect+ADEVs+Cy5‐miR138, Cy5‐miR138 were loaded into ADEVs using by Exo‐Fect transfection kit; Exo‐fect+Cy5‐miR138, Cy5‐miR138 were loaded using by Exo‐Fect transfection kit (without ADEVs); Exo‐fect+ADEVs+miR138, unstained miR138 were loaded into ADEVs using Exo‐Fect transfection kit; Bars, 50 μm (n = 3). (C) TLR7 was immunoprecipitated from BV2 cells by IgG / TLR7 / LAMP1 antibody, followed by assessment of miR138 / U6 expression by real‐time PCR. One‐way ANOVA followed by Bonferroni's post hoc test was used to determine the statistical significance among multiple groups (n = 3). (D) TLR7 was immunoprecipitated from HEK‐Null / HEK‐TLR7 cells by IgG/TLR7 antibody, followed by assessment of miR138 expression by real‐time PCR. One‐way ANOVA followed by Bonferroni's post hoc test was used to determine the statistical significance among multiple groups (n = 3). (E) The protein of TLR7 were pull down by miR‐138‐biotin / miR‐mut‐138‐biotin with Streptavidin agarose beads in BV2 cells. All data are presented as mean ± SD or SEM of three individual experiments. *,P < 0.05; **,P < 0.01; ***,P < 0.001 versus control group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33304479), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-27332_mouse-monoclonal-tlr7-antibody-4g6-310202416114724.jpg)
![Western Blot: TLR3 Antibody [NB100-56571] - Myocardial infarction (MI) increased TLR3 expression and its physical association with Trif in mouse myocardium. Heart samples were taken from infarct area at 4 weeks after MI. (A) and (B) show mRNA and protein levels of TLR3 in sham and MI hearts. n = 4 mice/group. Data are means +/- S.D. AP < 0.01 versus sham. Image collected and cropped by CiteAb from the following publication (//doi.wiley.com/10.1111/jcmm.13328) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR3-Antibody-Western-Blot-NB100-56571-img0009.jpg "<b>Biological Strategies Validation and Orthogonal Strategies Validation.</b>Western Blot: TLR3 Antibody [NB100-56571] - Myocardial infarction (MI) increased TLR3 expression and its physical association with Trif in mouse myocardium. Heart samples were taken from infarct area at 4 weeks after MI. (A) and (B) show mRNA and protein levels of TLR3 in sham and MI hearts. n = 4 mice/group. Data are means +/- S.D. AP < 0.01 versus sham. Image collected and cropped by CiteAb from the following publication (//doi.wiley.com/10.1111/jcmm.13328) licensed under a CC-BY license.")
![<b>Biological Strategies Validation and Orthogonal Strategies Validation.</b>Immunohistochemistry-Frozen: TLR3 Antibody [NB100-56571] - Frozen mouse eye tissue sections stained with TLR3, a retinal pigment epithelium (RPE) marker and DAPI. Top panel: TLR3 (red) colocalized with the RPE (green) marker. Bottom panel: Tissue stained with isotype control (no TLR3 Ab), RPE and DAPI. Data courtesy of Kleinman et al.](http://images.novusbio.com/fullsize/TLR3-Antibody-Immunohistochemistry-Frozen-NB100-56571-img0002.jpg)
![Flow Cytometry: TLR3 Antibody [NB100-56571] - Analysis using the FITC conjugate of NB100-56571. Staining of TLR3 in Balb/c mouse splenocytes using this antibody at 1 ug/10^6 cells. Green represents rabbit IgG isotype control this antibody; red represents anti-TLR3 antibody.](http://images.novusbio.com/fullsize/TLR3-Antibody-Flow-Cytometry-NB100-56571-img0008.jpg)
![Western Blot: TLR3 Antibody [NB100-56571] - Analysis of TLR3 in mouse spleen tissue lysate using NB100-56571 at 2 ug/ml.](http://images.novusbio.com/fullsize/TLR3-Antibody-Western-Blot-NB100-56571-img0005.jpg)
![Immunohistochemistry: TLR3 Antibody [NB100-56571] - Pig lung poisoned through aspiration with gastric juice and organophosphate (dimethoate EC40) after 48 hours of IC ventilation. Image from verified customer review.](http://images.novusbio.com/fullsize/TLR3-Antibody-Immunohistochemistry-NB100-56571-img0006.jpg)
![Flow Cytometry: TLR3 Antibody [NB100-56571] - Intracellular flow analysis of TLR3 in Balb/c mouse splenocytes and mouse RAW cells using TLR3 antibody (red) and isotype control antibody (green) at 1 ug/10^6 cells.](http://images.novusbio.com/fullsize/TLR3-Antibody-Flow-Cytometry-NB100-56571-img0001.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: TLR3 Antibody [NB100-56571] - siRNA was transfected at 50 nM for 48 hrs, and poly(I:C) was added at 100 ug/ml for 4 hrs before cell harvest. Negative control (NC) siRNA served as control. RNAiMAX transfection reagent was used in all the siRNA experiments. Panel shows the knockdown effects of siRNAs. Image collected and cropped by CiteAb from the following publication (//doi.wiley.com/10.1111/jcmm.13328) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR3-Antibody-Knockdown-Validated-NB100-56571-img0010.jpg)
![Western Blot: TLR3 Antibody [NB100-56571] - Myocardial infarction (MI) increased TLR3 expression & its physical association with Trif in mouse myocardium. Heart samples were taken from infarct area at 4 weeks after MI. (A) & (B) show mRNA & protein levels of TLR3 in sham & MI hearts. n = 4 mice/group. Data are means ± S.D. AP < 0.01 versus sham. (C) Representative immunohistochemistry images of heart sections stained for TLR3 (brown colour). An isotype IgG control was performed to verify the specificity of TLR3 reactivity. (D) Lysates of heart tissue were immunoprecipitated with anti‐TLR3 antibodies (IP: TLR3), followed by SDS–PAGE & immunoblotting (IB) with indicated antibodies. IP with isotype IgG (IP: IgG) was performed as a control to exclude the non‐specific binding of antibodies to cellular proteins. Green arrows indicate non‐specific bands. The association between TLR3 & Trif, but not MyD88, was detectable in sham myocardium & was increased in infarct myocardium. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28945004), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56571_rabbit-polyclonal-tlr3-antibody-310202415523938.jpg)
![Western Blot: TLR3 Antibody [NB100-56571] - Myocardial infarction (MI) increased TLR3 expression & its physical association with Trif in mouse myocardium. Heart samples were taken from infarct area at 4 weeks after MI. (A) & (B) show mRNA & protein levels of TLR3 in sham & MI hearts. n = 4 mice/group. Data are means ± S.D. AP < 0.01 versus sham. (C) Representative immunohistochemistry images of heart sections stained for TLR3 (brown colour). An isotype IgG control was performed to verify the specificity of TLR3 reactivity. (D) Lysates of heart tissue were immunoprecipitated with anti‐TLR3 antibodies (IP: TLR3), followed by SDS–PAGE & immunoblotting (IB) with indicated antibodies. IP with isotype IgG (IP: IgG) was performed as a control to exclude the non‐specific binding of antibodies to cellular proteins. Green arrows indicate non‐specific bands. The association between TLR3 & Trif, but not MyD88, was detectable in sham myocardium & was increased in infarct myocardium. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28945004), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56571_rabbit-polyclonal-tlr3-antibody-3102024165731.jpg)
![Immunohistochemistry: TLR3 Antibody [NB100-56571] - Myocardial infarction (MI) increased TLR3 expression & its physical association with Trif in mouse myocardium. Heart samples were taken from infarct area at 4 weeks after MI. (A) & (B) show mRNA & protein levels of TLR3 in sham & MI hearts. n = 4 mice/group. Data are means ± S.D. AP < 0.01 versus sham. (C) Representative immunohistochemistry images of heart sections stained for TLR3 (brown colour). An isotype IgG control was performed to verify the specificity of TLR3 reactivity. (D) Lysates of heart tissue were immunoprecipitated with anti‐TLR3 antibodies (IP: TLR3), followed by SDS–PAGE & immunoblotting (IB) with indicated antibodies. IP with isotype IgG (IP: IgG) was performed as a control to exclude the non‐specific binding of antibodies to cellular proteins. Green arrows indicate non‐specific bands. The association between TLR3 & Trif, but not MyD88, was detectable in sham myocardium & was increased in infarct myocardium. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28945004), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56571_rabbit-polyclonal-tlr3-antibody-310202415535158.jpg)
![Western Blot: TLR3 Antibody [NB100-56571] - TLR3‐knockout (TLR3‐KO) attenuated cardiac autophagy induced by MI. The infarct & remote tissues were separately sampled from the left ventricle after 4 weeks of MI. Accordingly, anterior & posterior tissues of the left ventricle were sampled from sham hearts as controls. (A) Representative Western blot images & quantitative analyses of autophagy markers. n = 4–8/group. Quantitative data are fold changes of WT‐sham. aP < 0.05, AP < 0.01 versus respective WT‐sham; bP < 0.05, BP < 0.01 versus respective WT‐MI. (B) Representative electron microphotographs of ultrathin sections of resin‐embedded heart biopsies. Arrows indicate autophagic vacuoles. (C) Lysates of infarct tissue were immunoprecipitated (IP), followed by SDS–PAGE & immunoblotting (IB) with indicated antibodies. IP with isotype IgG served as a control. Green arrows indicate non‐specific bands. Representative images were taken from four independent experiments. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28945004), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56571_rabbit-polyclonal-tlr3-antibody-310202415525214.jpg)
![Western Blot: TLR3 Antibody [NB100-56571] - A TLR3 agonist polyinosinic‐polycytidylic acid (poly(I:C)) induced autophagy in cultured cardiomyocytes through a TRIF‐dependent pathway. (A) Poly(I:C) increased autophagy markers in cultured H9c2 rat ventricular cells. (B) Poly(I:C) stimulated autophagosome formation but did not affect autophagic flux. Primary cultured neonatal rat ventricular myocytes (NRVMs) were transfected with a tandem mRFP‐GFP‐LC3 adenovirus for 24 hrs, followed by treatment with poly(I:C) (100 μg/ml, 4 hrs). Autophagosomes & autolysosomes were, respectively, visualized as yellow‐ & red‐only punctas under a confocal microscope. (C) An autophagic flux inhibitor chloroquine (CQ) induced accumulations of LC3‐II & p62/SQSTM1 proteins in H9c2 myocytes receiving poly(I:C) (100 μg/ml, 4 hrs). CQ was applied at 10 μM, immediately prior to poly(I:C). (D) Effects of indicated siRNA on poly(I:C)‐induced changes in autophagy markers in NRVMs. All the siRNAs were transfected at 50 nM for 48 hrs, & poly(I:C) was added at 100 μg/ml for 4 hrs before cell harvest. Negative control (NC) siRNA served as control. RNAiMAX transfection reagent was used in all the siRNA experiments. The upper panel shows the knockdown effects of siRNAs, & the lower panel shows representative Western blot images (presented from four independent experiments) & densitometry quantitative data (normalized into ‘fold of vehicle group’). All quantitative data are expressed as means ± S.D. aP < 0.05, AP < 0.01 versus vehicle; bP < 0.05, BP < 0.01 versus poly(I:C). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28945004), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56571_rabbit-polyclonal-tlr3-antibody-3102024168394.jpg)
![Western Blot: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Analysis of P65 using p65 antibody at 2 ug/mL in 30 ug of A) Ramos, B) Daudi, C) HeLa and D) mouse NIH 3T3 cell lysate.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-112A1021-Western-Blot-NB100-56712-img0013.jpg "Western Blot: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Analysis of P65 using p65 antibody at 2 ug/mL in 30 ug of A) Ramos, B) Daudi, C) HeLa and D) mouse NIH 3T3 cell lysate.")
![Simple Western: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Lane view shows a specific band for NFkB p65 in 1.0 mg/mL of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-112A1021-Simple-Western-NB100-56712-img0006.jpg)
![Western Blot: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Lysates of HeLa human cervical epithelial carcinoma cell line and Daudi human Burkitt's lymphoma cell line. PVDF membrane was probed with 1 ug/mL mouse anti-RelA/NFkB p65 monoclonal (NB100-56712, Novus Biologicals), followed by 1:2000 dilution of the appropriate HRP-conjugated secondary antibody, donkey anti-mouse IgG (HAF018).](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-112A1021-Western-Blot-NB100-56712-img0016.jpg)
![Immunohistochemistry-Paraffin: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Ovarian cystadenocarcinoma probed with p65 antibody at 5 ug/mL. Human tissue TMA was used for this test. Staining of formalin-fixed tissues is enhanced by boiling tissue sections in 10 mM sodium citrate buffer, pH 6.0 for 10-20 min followed by cooling at RT for 20 min.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-112A1021-Immunohistochemistry-Paraffin-NB100-56712-img0009.jpg)
![Flow Cytometry: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Intracellular staining of 293 HEK cells using 0.5 ug of p65 antibody. Green histogram represents the isotype control (p65) antibody. This NFkB p65 antibody was used for this test with an anti-mouse IgG PE conjugated secondary antibody.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-112A1021-Flow-Cytometry-NB100-56712-img0004.jpg)
![Simple Western: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Detection of p65 by Simple Western (JESS) in chemiluminescence in nuclear extract of reconstructed human epidermis lysate (about 600 ug/mL protein concentration).Antibody at 1:20. Simple Western image submitted by a verified customer review.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-112A1021-Simple-Western-NB100-56712-img0017.jpg)
![Blocking/Neutralizing: RelA/NFkB p65 [p Ser276] Inhibitor Peptide Set [NBP2-26505] - Effect of various p65-inhibitor peptides on binding of purified recombinant p65 protein to the DNA in vitro. Recombinant p65 protein (100 ng/sample) was incubated for 30 minutes with 50uM of various peptides in 0.025 ml and then assayed for DNA binding activity by EMSA (Please refer to Takada et al, 2004 for further details).](http://images.novusbio.com/fullsize/RelA-NFkB-p65-[p-Ser276]-Inhibitor-Peptide-Set-Blocking-Neutralizing-NBP2-26505-img0008.jpg "Blocking/Neutralizing: RelA/NFkB p65 [p Ser276] Inhibitor Peptide Set [NBP2-26505] - Effect of various p65-inhibitor peptides on binding of purified recombinant p65 protein to the DNA in vitro. Recombinant p65 protein (100 ng/sample) was incubated for 30 minutes with 50uM of various peptides in 0.025 ml and then assayed for DNA binding activity by EMSA (Please refer to Takada et al, 2004 for further details).")
![Blocking/Neutralizing: RelA/NFkB p65 [p Ser276] Inhibitor Peptide Set [NBP2-26505] - PTD-p65-P1 peptide inhibits TNF-induced NF-kB activation: KBM-5 cells were incubated with various concentrations of peptides for 1 hr and treated with 0.1nM TNF for 30 min. Nuclear extracts were prepared and NF-kB activation was analyzed by EMSA (Please refer to Takada et al, 2004 for further details).](http://images.novusbio.com/fullsize/RelA-NFkB-p65-[p-Ser276]-Inhibitor-Peptide-Set-Blocking-Neutralizing-NBP2-26505-img0009.jpg)
![Functional (Inhibition): RelA/NFkB p65 [p Ser276] Inhibitor Peptide Set [NBP2-26505] - TLR5/NF-kB/SEAPorter HEK 293 (NBP2-26277) cells were plated in 96-well plates at 5 x 10^4 cells/well for 16 h. Cells were preincubated with different concentrations (0, 1, 5, 10, 25 and 50 uM) of Inhibitory Peptide (NBP2-26505) and Control Peptide (NBP2-29334) for 1 h. Cells were then stimulated with 1 ng/ml Flagellin (NBP2-25289) for 24 h. Secreted alkaline phosphatase (SEAP) was analyzed using SEAPorter Assay Kit (NBP2-25285). *p < 0.05 versus control peptide at the corresponding concentrations (Mann-Whitney U test).](http://images.novusbio.com/fullsize/RelA-NFkB-p65-p-Ser276-Inhibitor-Peptide-Set-Functional-Inhibition-NBP2-26505-img0010.jpg)
![In vivo assay: IKK gamma Inhibitor Peptide Set [NBP2-26504] - NBD peptide blocks constitutive NF-kB as shown by EMSA. U266 cells were treated with 100 uM of control or NBD peptide for different time periods. Nuclear extracts were isolated and checked for NF-kB-DNA binding activity.](http://images.novusbio.com/fullsize/IKK-gamma-Inhibitor-Peptide-Set-In-vivo-assay-NBP2-26504-img0010.jpg "In vivo assay: IKK gamma Inhibitor Peptide Set [NBP2-26504] - NBD peptide blocks constitutive NF-kB as shown by EMSA. U266 cells were treated with 100 uM of control or NBD peptide for different time periods. Nuclear extracts were isolated and checked for NF-kB-DNA binding activity.")
![In vivo assay: IKK gamma Inhibitor Peptide Set [NBP2-26504] - NBD peptide blocks constitutive NF-kB activation in human multiple myeloma cells. U266 cells were treated with 100 uM of control (A & B) or NBD peptide (C & D) for 12 hr, cytospun, plated on glass slides, air dried for 1 hr at room temperature and fixed with cold acetone. Slides were blocked with 5% normal goat serum for 1 hr and then incubated with rabbit polyclonal anti-human p65 antibody (A & C) followed by Ig-Alexa 594 second step. In control peptide treated cells, p65 translocates to nucleus (A), whereas NBD peptide prevents translocation of p65 into the nucleus (C). B & D: Nuclear staining with DNA binding dye.](http://images.novusbio.com/fullsize/IKK-gamma-Inhibitor-Peptide-Set-In-vivo-assay-NBP2-26504-img0012.jpg)
![IKK gamma Inhibitor Peptide Set [NBP2-26504] - The IKK complex consists of IKKalpha + IKKbeta+ NEMO. NEMO (IKKgamma/NF-kB Essential MOdulator) is a scaffold protein required for the kinase activity of IKKalpha + IKKbeta. NBD (NEMO Binding Domain) inhibits formation of the IKK complex (IKKalpha + IKKbeta+ NEMO) by binding to NEMO and blocking IKK complex formation. In this regard, NBD is considered to be an 'IKKalpha and IKKBeta decoy' Blocking IKK complex formation suppresses downstream events in the NF-kB signaling pathway that rely on the IKK complex including phosphorylation of IkBalpha, and subsequence IkBalpha ubiquination, degradation and release of NF-kB. Hence, NF-kB is retained in the cytoplasm in its inactive state.](http://images.novusbio.com/fullsize/IKK-gamma-Inhibitor-Peptide-Set-NBP2-26504-img0014.jpg)
![Functional (Inhibition): IKK gamma Inhibitor Peptide Set [NBP2-26504] - TLR5/NF-kB/SEAPorter HEK 293 (NBP2-26277) cells were plated in 96-well plates at 5 x 10^4 cells/well for 16 h. Cells were preincubated with different concentrations (0, 1, 5, 10, 25 and 50 uM) of Inhibitory Peptide (NBP2-26504) and Control Peptide (NBP2-29334) for 1 h. Cells were then stimulated with 1 ng/ml Flagellin (NBP2-25289) for 24 h. Secreted alkaline phosphatase (SEAP) was analyzed using SEAPorter Assay Kit (NBP2-25285). *p < 0.05 versus control peptide at the corresponding concentrations (Mann-Whitney U test).](http://images.novusbio.com/fullsize/IKK-gamma-Inhibitor-Peptide-Set-Functional-Inhibition-NBP2-26504-img0016.jpg)
![Immunohistochemistry-Paraffin: TLR6 Antibody (86B1153.2) [NB100-56536] - Tonsil probed with TLR6 antibody at 5 ug/ml. Novus's human tissue TMA was used for this test. Staining of formalin-fixed tissues is enhanced by boiling tissue sections in 10 mM sodium citrate buffer, pH 6.0 for 10-20 min followed by cooling at RT for 20 min.](http://images.novusbio.com/fullsize/TLR6-Antibody-86B1153-2-Immunohistochemistry-Paraffin-NB100-56536-img0007.jpg "Immunohistochemistry-Paraffin: TLR6 Antibody (86B1153.2) [NB100-56536] - Tonsil probed with TLR6 antibody at 5 ug/ml. Novus's human tissue TMA was used for this test. Staining of formalin-fixed tissues is enhanced by boiling tissue sections in 10 mM sodium citrate buffer, pH 6.0 for 10-20 min followed by cooling at RT for 20 min.")
![Flow (Intracellular): TLR6 Antibody (86B1153.2) [NB100-56536] - Analysis using the PE conjugate of NB100-56536. Staining of TLR6 in Ramos cells using this antibody. 5 ug/10^6 cells. Shaded histogram represents Ramos cells without antibody; green represents isotype control (BD Pharmingen); red represents this antibody.](http://images.novusbio.com/fullsize/TLR6-Antibody-86B1153-2-Flow-Intracellular-NB100-56536-img0014.jpg)
![Flow Cytometry: TLR6 Antibody (86B1153.2) [NB100-56536] - Cell surface analysis of TLR6 antibody in 10^6 human monocytes using 0.5 ug of this antibody. Shaded histogram represents cells without antibody; green represents isotype control antibody ; red represents anti-TLR6 antibody. goat anti-mouse IgG PE conjugated secondary antibody was used.](http://images.novusbio.com/fullsize/TLR6-Antibody-86B1153-2-Flow-Cytometry-NB100-56536-img0006.jpg)
![Immunocytochemistry/Immunofluorescence: LAMP-2/CD107b Antibody [NB300-591] - Analysis of LAMP-2/CD107b in HeLa Cells. Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with a LAMP-2/CD107b polyclonal antibody at a dilution of 1:20 overnight at 4C, washed with PBS and incubated with a DyLight-488 conjugated secondary antibody. LAMP2 staining (green), F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue) is shown. Images were taken at 60X magnification.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-Immunocytochemistry-Immunofluorescence-NB300-591-img0012.jpg "Immunocytochemistry/Immunofluorescence: LAMP-2/CD107b Antibody [NB300-591] - Analysis of LAMP-2/CD107b in HeLa Cells. Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with a LAMP-2/CD107b polyclonal antibody at a dilution of 1:20 overnight at 4C, washed with PBS and incubated with a DyLight-488 conjugated secondary antibody. LAMP2 staining (green), F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue) is shown. Images were taken at 60X magnification.")
![Immunohistochemistry-Paraffin: LAMP-2/CD107b Antibody [NB300-591] - Normal deparaffinized Human placenta tissue tissues stained with anti-LAMP-2/CD107b.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-Immunohistochemistry-Paraffin-NB300-591-img0015.jpg)
![Immunohistochemistry-Paraffin: LAMP-2/CD107b Antibody [NB300-591] - Both normal and cancer biopsies of deparaffinized Human prostate carcinoma tissues stained with anti-LAMP-2/CD107b.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-Immunohistochemistry-Paraffin-NB300-591-img0016.jpg)
![Western Blot: LAMP-2/CD107b Antibody [NB300-591] - Analysis of 25ug of NRK cell lysates using anti-LAMP-2/CD107b.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-Western-Blot-NB300-591-img0017.jpg)
![Western Blot: LAMP-2/CD107b Antibody [NB300-591] - Validation of subcellular fractionation and immunocytochemistry. RLC proteins are present at ER microsomes. Lysates from 7 DIV cortical neurons were subjected to differential centrifugation to isolate nuclear pellet (P1), postnuclear supernatant (PNS), mitochondrial pellet (P2), and ER microsomal pellet (P3), as depicted in the graphic on the right. Image collected and cropped by CiteAb from the following publication (www.onlinelibrary.wiley.com/doi/10.15252/embr.201744853) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-Western-Blot-NB300-591-img0020.jpg)
![Immunocytochemistry/Immunofluorescence: LAMP-2/CD107b Antibody [NB300-591] - Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with a LAMP-2/CD107b polyclonal antibody at a dilution of 1:100 overnight at 4 C, washed with PBS and incubated with a DyLight-488 conjugated secondary antibody and nuclei with DAPI (blue) is shown.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-Immunocytochemistry-Immunofluorescence-NB300-591-img0019.jpg)
![Western Blot: LAMP-2/CD107b Antibody [NB300-591] - Analysis of 10 ug of HeLa (left panel), NIH/3T3 (middle panel) and NRK (right panel) whole cell lysates using anti-LAMP-2/CD107b.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-Western-Blot-NB300-591-img0018.jpg)
![Immunocytochemistry/Immunofluorescence: LAMP-2/CD107b Antibody [NB300-591] - Analysis of LAMP-2/CD107b (green) in NIH/3T3 cells.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-Immunocytochemistry-Immunofluorescence-NB300-591-img0013.jpg)
![Immunohistochemistry-Paraffin: LAMP-2/CD107b Antibody [NB300-591] - Both normal and cancer biopsies of deparaffinized Human tonsils were stained with anti-LAMP-2/CD107b.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-Immunohistochemistry-Paraffin-NB300-591-img0014.jpg)
![Western Blot: LAMP-2/CD107b Antibody [NB300-591] - Exposure of rat primary microglial cells (rPMs) to combined antiretroviral therapy (cART) cocktail resulted in impaired lysosomal function. rPMs were seeded into six-well plates & treated with cART (5 µM each of tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), & dolutegravir (DTG)) for the indicated time periods. (A,B) Exposure of microglia to cART resulted in a significant decrease in expression of lysosomal-associated membrane protein 2 (LAMP2) at 6 to 24 h post-treatment. (C) Representative bar graph showing cART-mediated significantly increased lysosomal membrane permeabilization (LMP) (24 h). (D,E) Microglia exposed to cART demonstrated a significant decrease in levels of mature cathepsin D (mCTSD) at 24 h post-treatment. (F) Representative bar graph showing exposure of cART significantly reduced the CTSD activity in rPMs (24 h). (G) Representative bar graph showing cART-mediated increased lysosomal pH in rPMs. (H,I) Acridine orange staining showing increased green color & reduced red color in cART-treated rPMs. H2O2 was used as a positive control for lysosome damage. Data is from three independent experiments. Actin beta (ACTB) served as a protein loading control for western blots. Data are expressed as means ± SEM & were analyzed using student t-test or one-way ANOVA. *, p < 0.05 vs. control; N.S., non-significant. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31569373), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-591_rabbit-polyclonal-lamp-2-cd107b-antibody-310202416175213.jpg)
![Western Blot: LAMP-2/CD107b Antibody [NB300-591] - HSPA overexpression abrogated cART-mediated impairment of lysosomal function. Control rPMs & heat shock protein family A (HSPA) overexpressing rPMs were seeded into six-well plates subjected to various treatments for 24 h. Protein homogenates were prepared for the detection of the indicated molecules. (A,B) Representative western blots showing overexpressing HSPA in rPMs reversed cART-mediated downregulation of LAMP2 & mCTSD expression levels. (C) Representative bar graph showing overexpression of HSPA in rPMs protected lysosomal pH. (D,E) Representative bar graphs showing HSPA protected LMP (D), & CTSD activity (E) in cART-treated rPMs. For all western blots, ACTB served as a protein loading control. Data is from three independent experiments & is expressed as means ± SEM & were analyzed using student t-test or one-way ANOVA. *, p < 0.05 vs. control; #, p < 0.05 vs. cART. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31569373), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-591_rabbit-polyclonal-lamp-2-cd107b-antibody-31020241618933.jpg)
![Immunocytochemistry/Immunofluorescence: NFATC2/NFAT1 Antibody (25A10.D6.D2) [NB300-504] - Analysis of NFATc2 (green) in HeLa cells. Formalin fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 10 minutes at room temperature and blocked with 1% Blocker BSA for 15 minutes at room temperature. Cells were left untreated (left panel) or treated with 1uM staurosporine (right panel) for 3 hours and probed with a NFATc2 monoclonal antibody, at a dilution of 1:100 for at least 1 hour at room temperature, washed with PBS, and incubated with DyLight 488 goat anti-mouse IgG secondary antibody at a dilution of 1:400 for 30 minutes at room temperature. F-Actin (red) was stained with DyLight 554 Phalloidin and nuclei (blue) were stained with Hoechst 33342 dye.](http://images.novusbio.com/fullsize/NFATC2-NFAT1-Antibody-25A10-D6-D2-Immunocytochemistry-Immunofluorescence-NB300-504-img0010.jpg "Immunocytochemistry/Immunofluorescence: NFATC2/NFAT1 Antibody (25A10.D6.D2) [NB300-504] - Analysis of NFATc2 (green) in HeLa cells. Formalin fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 10 minutes at room temperature and blocked with 1% Blocker BSA for 15 minutes at room temperature. Cells were left untreated (left panel) or treated with 1uM staurosporine (right panel) for 3 hours and probed with a NFATc2 monoclonal antibody, at a dilution of 1:100 for at least 1 hour at room temperature, washed with PBS, and incubated with DyLight 488 goat anti-mouse IgG secondary antibody at a dilution of 1:400 for 30 minutes at room temperature. F-Actin (red) was stained with DyLight 554 Phalloidin and nuclei (blue) were stained with Hoechst 33342 dye.")
![Immunohistochemistry-Paraffin: NFATC2/NFAT1 Antibody (25A10.D6.D2) [NB300-504] - Both normal and cancer biopsies of deparaffinized Human spleen tissue tissues.](http://images.novusbio.com/fullsize/NFATC2-NFAT1-Antibody-25A10-D6-D2-Immunohistochemistry-Paraffin-NB300-504-img0012.jpg)
![Chromatin Immunoprecipitation: NFATC2/NFAT1 Antibody (25A10.D6.D2) [NB300-504] - IP performed using Matrix ChIP assay with 1.0ul/100ul well of NFATc2 mab. Chromatin aliquots from ~1x10^5 cells used per ChIP pull-down. Quantitative PCR data done x4 using 1ul of eluted DNA in 2ul SYBR real-time PCR reactions containing primers to amplify exon-1 or exon-28 of LAMC1. PCR calibration curves generated per primer pair from a series of sheared total genomic DNA. ChIP presented relative to the total amount of input chromatin. Results represent mean +/- SEM for 3 experiments. Representation of rat LAMC1 locus shown above data where boxes represent exons (black = translated regions, white = untranslated regions); zigzag line represents an intron, & straight line represents upstream sequence. Regions amplified by LAMC1 primers are represented by black bars. Data courtesy of the Innovators Program.](http://images.novusbio.com/fullsize/NFATC2-NFAT1-Antibody-25A10-D6-D2-Chromatin-Immunoprecipitation-NB300-504-img0009.jpg)
![Immunocytochemistry/Immunofluorescence: NFATC2/NFAT1 Antibody (25A10.D6.D2) [NB300-504] - Analysis of NFATc2 using NFATc2 Monoclonal Antibody (25A10.D6.D2) shows staining in Hela Cells. NFATc2 (green), F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue) is shown. Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with an antibody recognizing NFATc2 at a dilution of 1:20 over night at 4C, washed with PBS and incubated with a DyLight-488 conjugated.](http://images.novusbio.com/fullsize/NFATC2-NFAT1-Antibody-25A10-D6-D2-Immunocytochemistry-Immunofluorescence-NB300-504-img0006.jpg)
![Immunocytochemistry/Immunofluorescence: NFATC2/NFAT1 Antibody (25A10.D6.D2) [NB300-504] - Analysis of NFATc2 using NFATc2 Monoclonal Antibody (25A10.D6.D2) shows staining in MCF-7 Cells. NFATc2 (green), F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue) is shown. Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with an antibody recognizing NFATc2 at a dilution of 1:20 over night at 4C, washed with PBS and incubated with a DyLight-488 conjugated.](http://images.novusbio.com/fullsize/NFATC2-NFAT1-Antibody-25A10-D6-D2-Immunocytochemistry-Immunofluorescence-NB300-504-img0007.jpg)
![Immunocytochemistry/Immunofluorescence: NFATC2/NFAT1 Antibody (25A10.D6.D2) [NB300-504] - Analysis of NFATc2 using NFATc2 Monoclonal Antibody (25A10.D6.D2) shows staining in U251 Cells. NFATc2 (green), F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue) is shown. Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with an antibody recognizing NFATc2 at a dilution of 1:20 over night at 4C, washed with PBS and incubated with a DyLight-488 conjugated.](http://images.novusbio.com/fullsize/NFATC2-NFAT1-Antibody-25A10-D6-D2-Immunocytochemistry-Immunofluorescence-NB300-504-img0008.jpg)
![Immunohistochemistry-Paraffin: NFATC2/NFAT1 Antibody (25A10.D6.D2) [NB300-504] - Cancer biopsies of deparaffinized Human colon carcinoma tissues.](http://images.novusbio.com/fullsize/NFATC2-NFAT1-Antibody-25A10-D6-D2-Immunohistochemistry-Paraffin-NB300-504-img0004.jpg)
![Immunohistochemistry-Paraffin: NFATC2/NFAT1 Antibody (25A10.D6.D2) [NB300-504] - Both normal and cancer biopsies of deparaffinized Human tonsil tissues.](http://images.novusbio.com/fullsize/NFATC2-NFAT1-Antibody-25A10-D6-D2-Immunohistochemistry-Paraffin-NB300-504-img0011.jpg)
![TRAF6 Inhibitor Peptide Set [NBP2-26506] - The TRAF6 inhibitory peptide inhibits osteoclast ifferentiation: RAW264.7 cells were plated on 24-well plates and stimulated with RANKL and M-CSF and incubated in the presence of different concentrations of control peptide (PTD) or the TRAF6. The TRAF6 at the concentration above 30 uM suppressed osteoclast differentiation.](http://images.novusbio.com/fullsize/TRAF6-Inhibitor-Peptide-Set-NBP2-26506-img0002.jpg "TRAF6 Inhibitor Peptide Set [NBP2-26506] - The TRAF6 inhibitory peptide inhibits osteoclast ifferentiation: RAW264.7 cells were plated on 24-well plates and stimulated with RANKL and M-CSF and incubated in the presence of different concentrations of control peptide (PTD) or the TRAF6. The TRAF6 at the concentration above 30 uM suppressed osteoclast differentiation.")